Tiziana Life Sciences, which is developing antibody therapies to combat NASH, Crohn's disease, MS, and cancer, raised $4.4 million by offering 442,910 shares at $9.90. The offer price is roughly equal to the as-converted price of Tiziana's common...read more
As many as 7 IPOs could raise about $450 million in the week ahead, including 6 healthcare deals. Don't expect all of them to get done. IPOs have sold off alongside the broader markets, while the VIX Volatility Index is in the "IPO postponement zone." read more
Tiziana Life Sciences, which is developing antibody therapies to combat NASH, Crohn's disease, MS, and cancer, lowered the proposed deal size for its upcoming Nasdaq IPO on Thursday. The company is listed on the AIM under the ticker TILS.
The London, United...read more
Tiziana Life Sciences, which is developing antibody therapies to combat NASH, Crohn's disease, MS, and cancer, announced terms for its Nasdaq IPO on Tuesday. The London, United Kingdom-based company plans to raise $16 million by offering 1.575 million ADSs...read more
Tiziana Life Sciences prices downsized $4 million US offering at $9.90
Tiziana Life Sciences, which is developing antibody therapies to combat NASH, Crohn's disease, MS, and cancer, raised $4.4 million by offering 442,910 shares at $9.90. The offer price is roughly equal to the as-converted price of Tiziana's common...read more
US IPO Week Ahead: Micro-cap healthcare dominates week with up to 7 IPOs
As many as 7 IPOs could raise about $450 million in the week ahead, including 6 healthcare deals. Don't expect all of them to get done. IPOs have sold off alongside the broader markets, while the VIX Volatility Index is in the "IPO postponement zone."read more
Antibody biotech Tiziana Life Sciences decreases proposed US IPO deal size
Tiziana Life Sciences, which is developing antibody therapies to combat NASH, Crohn's disease, MS, and cancer, lowered the proposed deal size for its upcoming Nasdaq IPO on Thursday. The company is listed on the AIM under the ticker TILS. The London, United...read more
Antibody biotech Tiziana Life Sciences sets terms for $16 million Nasdaq IPO
Tiziana Life Sciences, which is developing antibody therapies to combat NASH, Crohn's disease, MS, and cancer, announced terms for its Nasdaq IPO on Tuesday. The London, United Kingdom-based company plans to raise $16 million by offering 1.575 million ADSs...read more